tradingkey.logo

Eterna Therapeutics Inc

ERNA
View Detailed Chart
0.376USD
-0.304-44.66%
Close 02/06, 16:00ETQuotes delayed by 15 min
2.95MMarket Cap
0.01P/E TTM

Eterna Therapeutics Inc

0.376
-0.304-44.66%
Intraday
1m
30m
1h
D
W
M
D

Today

-44.66%

5 Days

-69.16%

1 Month

-70.37%

6 Months

-77.60%

Year to Date

-68.64%

1 Year

-92.62%

View Detailed Chart

Key Insights

Eterna Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 222 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eterna Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
222 / 392
Overall Ranking
461 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Eterna Therapeutics Inc Highlights

StrengthsRisks
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Growing
The company is in a growing phase, with the latest annual income totaling USD 582.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 582.00K.
Overvalued
The company’s latest PE is 0.01, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 35.92K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Eterna Therapeutics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Eterna Therapeutics Inc Info

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Ticker SymbolERNA
CompanyEterna Therapeutics Inc
CEOLuther (Sanjeev)
Websitehttps://www.ernexatx.com/
KeyAI